

QUESTION NO.- 1250370.003  
DE10034627A1[request changes](#) [rate this report](#) [frequently asked questions \(FAQs\)](#)[Title List](#)  
[Citation Information](#)

Copyright 2004 Nerac Inc. All Rights Reserved

June 9, 2004

Information Specialist- Kim Spytek

## TO ORDER DOCUMENTS:


- Follow this link: <http://www.nerac.com/documents>
- Call Nerac Document Services at 860-872-9331
- Fax your request to 860-875-1749
- Or send e-mail to [documents@nerac.com](mailto:documents@nerac.com)

Please reference the NDN number of the document(s) you wish to order.

## Citations from GERMANY FULLTEXT PATENTS: GER

1. NDN 203-0331-5410-6: Aryl-substituierte Oxazolidinone with Cytokin's inhibitorischer effect

---

**1. Aryl-substituierte Oxazolidinone with Cytokin's inhibitorischer effect**  
GER 01-31-2002 10034627 NDN- 203-0331-5410-6

INVENTOR(S)- Fischer, RoDiger, Dr. 50933 Koeln DE  
INVENTOR(S)- MoOller, Ulrich, Dr. 42111 Wuppertal DE  
INVENTOR(S)- Handke, Gabriele, Dr. 42489 WoOlfrath DE  
INVENTOR(S)- Petesch, Nicole, Dr. 42119 Wuppertal DE  
INVENTOR(S)- Schmeck, Carsten, Dr. 42119 Wuppertal DE  
INVENTOR(S)- Kretschmer, Axel, Dr. 42113 Wuppertal DE  
INVENTOR(S)- Nielsch, Ulrich, Dr. 40547 DoOsseldorf DE  
INVENTOR(S)- Bremm, Klaus-Dieter, Dr. 45661 Recklinghausen DE

**APPLICANT(S)**- Bayer AG 51373 Leverkusen DE

**PATENT NUMBER**- 10034627/DE-A1

**PATENT APPLICATION NUMBER**- 10034627

**DATE FILED**- 07-17-2000

**DOCUMENT TYPE**- A1, DOCUMENT LAID OPEN (FIRST PUBLICATION)

**PUBLICATION DATE**- 01-31-2002

**INTERNATIONAL PATENT CLASS**- C07D41310; C07D26320; A61K03144; C07D21324;

C07D41310

**PATENT APPLICATION PRIORITY**- 10034627, A

**PRIORITY COUNTRY CODE**- DE, Germany, Ged. Rep. of

**PRIORITY DATE**- 07-17-2000

**FILING LANGUAGE**- German

**LANGUAGE**- German

The present invention involves new Aryl-substituierte Oxazolidinone with Cytokin's inhibitorischer effect, procedures about her/its/their manufacture and her/its/their application of drug, especially to the treatment from through the tumor Necrosis factor (TNF) of caused effects like for example arteriosclerosis.

**EXEMPLARY CLAIMS**- 1. Aryl - Oxazolidinone of the general formula (I) replaced ID=33/1 HE=33 WI=66 TI=CHE > in derd for a cyclischen hydrocarbon rest, his/its kann,in of the b gets along for example an Aryl/rest, that replaces for his part with one or several rests of Rd, for CH2 gets along the values 0 undm until 4 he/lt assume kann,in a can stand with 1 to 3 Heteroatomen for hydrogen, a hydrocarbon rest or a filling or partially unsatisfied or aromatic Heterocyclics, selected O;in the e from S, N, can stand for amino, mono -. 2. Aryl - If Oxazolidinone of the general formula (I) in derd replaced for an aromatic hydrocarbon rest, preferably Phenyl, that replaces for his part with one or several rests of Rd, gets along his/its kann,in of the b for CH2 gets along the values 0, 1, undm or 2 assumes kann,in he/lt a can stand over the position 2 for hydrogen, a hydrocarbon rest or a filling or partially unsatisfied Heterocyclics, preferably -. or 4 - flited Pyridin or Piperidin;in the e can stand for amino, mono -. or di -. (C1). C4. Alkylamino Hydroxy C1. C4. Alkoxy this for his part can have replaced with a hydrocarbon rest, preferably Phenyl, with what for the case that stands d for Phenyl, b preferably ortho -. or parastoandig at d, and for the case, is tied up that of m = 0 ls, a preferably ortho -. 3. Aryl - Oxazolidinone of the general formula (I) in derd replaced for Phenyl, that replaces for his part through one or several remains of Rd, his/its kann,n of the b stands for CH2 gets along the values 0 undm, or 1 assumes kann,in he/lt a can stand over the position 2 for hydrogen, or a filling or partially unsatisfied Heterocyclics, preferably -. or 4-flited Pyridin C1. C4. Alkylamino Hydroxy C1. C4. Alkoxy this for his part can have replaced with a hydrocarbon rest, preferably Phenyl,in the b preferably ortho -. or para - constantly at d is tied up, and for the case that of m = 0 is a 4. Connections .

NO-DESCRIPTORS .

The information contained in this report has been obtained from one or more copyrighted sources under the authority of the copyright owners. No reproduction or further dissemination of this report or its individual articles may be made without the express written consent of Nerac, Inc. In each instance.